<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112552</url>
  </required_header>
  <id_info>
    <org_study_id>13-02-058</org_study_id>
    <secondary_id>NCI-2013-01226</secondary_id>
    <secondary_id>13-02-058</secondary_id>
    <secondary_id>P30CA013330</secondary_id>
    <nct_id>NCT02112552</nct_id>
  </id_info>
  <brief_title>Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer</brief_title>
  <official_title>A Pilot Phase II Trial of Intravenous Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation in Patients With Advanced Stage Uterine Serous Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albert Einstein College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Albert Einstein College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot, phase II trial studies the side effects and how well paclitaxel given into the&#xD;
      vein and carboplatin given directly into the abdominal cavity (intraperitoneally) followed by&#xD;
      radiation therapy work in treating patients with stage IIIC-IV serous uterine cancer. Drugs&#xD;
      used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the&#xD;
      growth of tumor cells, either by killing the cells, stopping them from dividing, or stopping&#xD;
      them from spreading. Giving the drugs in different ways may kill more tumor cells. Radiation&#xD;
      therapy uses high-energy x-rays to kill tumor cells. Giving chemotherapy followed by&#xD;
      radiation therapy may be an effective treatment for uterine cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the toxicity (as defined by National Cancer Institute [NCI] Common Toxicity&#xD;
      Criteria version [v.] 4.0) of weekly intravenous (IV) paclitaxel with intraperitoneal (IP)&#xD;
      carboplatin chemotherapy given every third week, followed by radiation therapy (RT) in&#xD;
      patients with advanced stage uterine serous cancer (USC).&#xD;
&#xD;
      II. To determine the feasibility of this regimen in women with advanced stage USC.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the frequency and the reasons for early discontinuation of the study treatments.&#xD;
&#xD;
      II. To describe patient-reported quality of life parameters at specified time points during&#xD;
      the study using validated questionnaires: European Organization for Research and the&#xD;
      Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and QLQ-ovarian cancer&#xD;
      module (OV)28.&#xD;
&#xD;
      TERTIARY OBJECTIVES:&#xD;
&#xD;
      I. To define patterns of recurrence (e.g. local versus distant) and progression-free survival&#xD;
      in patients with advanced and recurrent USC treated with dose dense IV paclitaxel and IP&#xD;
      carboplatin therapy.&#xD;
&#xD;
      II. To correlate surrogate endpoint biomarkers that is performed in standard histology&#xD;
      processing (estrogen receptor and progesterone receptor status as well as human epidermal&#xD;
      growth factor 2 [Her2/neu] status) with progression-free survival and prognosis.&#xD;
&#xD;
      III. To assess the potential late effects of combined intraperitoneal chemotherapy and&#xD;
      radiotherapy on the gastrointestinal, genitoureteral, bone marrow and other body systems&#xD;
      beginning at 6 months post treatment completion during routine office visits.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      CHEMOTHERAPY: Patients receive paclitaxel intravenously (IV) over 1 hour on days 1, 8, and 15&#xD;
      and carboplatin intraperitoneally (IP) on day 1. Treatment repeats every 21 days for up to 6&#xD;
      courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      RADIATION: At provider discretion, patients may undergo 3-dimensional (3D) conformal or&#xD;
      intensity-modulated radiation therapy (IMRT) 5 days a week for 5 weeks (weeks 19-23).&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months for 2 years,&#xD;
      every 6 months for 3 years, and then yearly thereafter for up to 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accrual&#xD;
  </why_stopped>
  <start_date type="Actual">April 2014</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Degree of tolerability, estimated by the proportion of participants who complete 6 treatment cycles of IP carboplatin</measure>
    <time_frame>Up to 18 weeks</time_frame>
    <description>At the end of the study, the proportion of patients who tolerated the therapy will be estimated, along with corresponding 95% confidence intervals. Reasons for discontinuation of therapy will be categorized and summarized by computing frequencies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>The duration of time from start of treatment to time of progression, or death, whichever happens first, assessed at 1 year</time_frame>
    <description>The proportion of responders at one year will be estimated with the Kaplan-Meier method. Surrogate endpoint biomarkers including estrogen, progesterone, and Her2/neu receptor status will be correlated with progression-free survival using the Cox Proportional Hazards model, provided the availability of a sufficient number of events.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Endometrial Serous Adenocarcinoma</condition>
  <condition>Stage IIIA Uterine Corpus Cancer</condition>
  <condition>Stage IIIB Uterine Corpus Cancer</condition>
  <condition>Stage IIIC1 Uterine Corpus Cancer</condition>
  <condition>Stage IIIC2 Uterine Corpus Cancer</condition>
  <condition>Stage IVA Uterine Corpus Cancer</condition>
  <condition>Stage IVB Uterine Corpus Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CHEMOTHERAPY: Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IP on day 1. Treatment repeats every 21 days for up to 6 courses (weeks 1-18) in the absence of disease progression or unacceptable toxicity.&#xD;
RADIATION: At provider discretion, patients may undergo 3D conformal or IMRT 5 days a week for 5 weeks (weeks 19-23).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>Anzatax</other_name>
    <other_name>TAX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Given IP</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>3-Dimensional Conformal Radiation Therapy</intervention_name>
    <description>Undergo 3D conformal radiation therapy</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>3D-CRT</other_name>
    <other_name>Conformal Therapy</other_name>
    <other_name>Radiation Conformal Therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intensity-Modulated Radiation Therapy</intervention_name>
    <description>Undergo IMRT</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>IMRT</other_name>
    <other_name>Intensity Modulated RT</other_name>
    <other_name>Intensity-Modulated Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (paclitaxel, carboplatin, radiotherapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological/cytologically documented primary International Federation of Gynecology&#xD;
             and Obstetrics (FIGO) stage 3C1, 3C2, stage 4A, and 4B uterine serous carcinoma; in&#xD;
             addition, certain stage 3A and B disease are also allowed&#xD;
&#xD;
               -  Residual disease after primary surgery:&#xD;
&#xD;
                    -  Eligible:&#xD;
&#xD;
                         -  Stage 3A and B (pelvic, but confined to adnexa or vagina), residual&#xD;
                            disease present&#xD;
&#xD;
                         -  Stage 3CI (pelvic node positive)&#xD;
&#xD;
                         -  Stage 3CII (para-aortic node positive)&#xD;
&#xD;
                         -  Stage 4A (bladder or pelvic bowel)&#xD;
&#xD;
                         -  Stage 4B (distant metastases [mets] including abdominal mets),&#xD;
                            completely resected&#xD;
&#xD;
                    -  Not eligible&#xD;
&#xD;
                         -  Stage 3A and B (pelvic, but confined to adnexa or vagina), completely&#xD;
                            resected&#xD;
&#xD;
                         -  Stage 4B (distant mets including abdominal mets), residual disease&#xD;
                            present&#xD;
&#xD;
          -  All patients must have a procedure for determining diagnosis of high-risk uterine&#xD;
             cancer (HRUC); minimum surgical intervention required is tissue biopsy (may be from&#xD;
             endometrium), if significant clinical evidence exists to support a stage 3 or 4&#xD;
             diagnosis; as per the discretion of the surgeon, complete surgical staging should&#xD;
             include: total abdominal hysterectomy, bilateral salpingo-oophorectomy, peritoneal&#xD;
             washings, omental biopsy and lymph node samplings; this is typically the standard&#xD;
             unless the disease is bulky or the clinician feels the patient would be best served by&#xD;
             chemotherapy and radiation therapy after histologic diagnosis is confirmed&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of =&lt; 2&#xD;
&#xD;
          -  Written voluntary informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastasis to the lung, bone or brain; typically, most stage 4 uterine&#xD;
             papillary serous cancer (UPSC) is confined to the abdomen on presentation&#xD;
&#xD;
          -  Serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate pyruvate&#xD;
             transaminase (SGPT) &gt; 2.5 times the institutional upper limit of normal (ULN)&#xD;
&#xD;
          -  Total serum bilirubin &gt; 1.5 mg/dl&#xD;
&#xD;
          -  Serum creatinine &gt; 2.0 mg/dl&#xD;
&#xD;
          -  Platelets &lt; 100,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &lt; 1500/mm^3&#xD;
&#xD;
          -  Hemoglobin &lt; 8.0 g/dl (the patient may be transfused prior to study entry)&#xD;
&#xD;
          -  History of abdominal/pelvic radiation therapy&#xD;
&#xD;
          -  Severe or uncontrolled, concurrent medical disease (e.g. uncontrolled diabetes,&#xD;
             unstable angina, myocardial infarction within 6 months, congestive heart failure,&#xD;
             etc.)&#xD;
&#xD;
          -  Patients with dementia or altered mental status that would prohibit the giving and&#xD;
             understanding of informed consent at the time of study entry&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marina Frimer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein College of Medicine</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystadenocarcinoma, Serous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

